[{"id":"cee8aba7-65f5-4dfb-8178-d79ff5369a64","acronym":"","url":"https://clinicaltrials.gov/study/NCT04999761","created_at":"2021-08-11T15:53:36.773Z","updated_at":"2024-07-02T16:35:19.007Z","phase":"Phase 1","brief_title":"AB122 Platform Study","source_id_and_acronym":"NCT04999761","lead_sponsor":"Taiho Pharmaceutical Co., Ltd.","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Cyramza (ramucirumab) • Lytgobi (futibatinib) • Yutuo (zimberelimab) • Lonsurf (trifluridine/tipiracil) • Jeselhy (pimitespib) • pamufetinib (TAS-115)"],"overall_status":"Recruiting","enrollment":" Enrollment 715","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-02-16"},{"id":"3c9529ef-684d-40e0-abc9-1500bd742be6","acronym":"BrUOG 387","url":"https://clinicaltrials.gov/study/NCT05655598","created_at":"2022-12-19T14:58:37.717Z","updated_at":"2024-07-02T16:35:36.916Z","phase":"Phase 1","brief_title":"TAS-116 Plus Palbociclib in Breast and Rb-[] Cancer","source_id_and_acronym":"NCT05655598 - BrUOG 387","lead_sponsor":"Brown University","biomarkers":" HER-2","pipe":" | ","alterations":" PIK3CA mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Jeselhy (pimitespib)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 09/12/2023","start_date":" 09/12/2023","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-09-14"},{"id":"73343190-c6f4-42f9-9309-f426699e9323","acronym":"","url":"https://clinicaltrials.gov/study/NCT02965885","created_at":"2021-01-18T14:34:41.227Z","updated_at":"2024-07-02T16:36:55.044Z","phase":"Phase 1a/1b","brief_title":"A Study of TAS-116 in Patients With Solid Tumors","source_id_and_acronym":"NCT02965885","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" HER-2 positive • EGFR mutation • ALK translocation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jeselhy (pimitespib)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 07/10/2017","start_date":" 07/10/2017","primary_txt":" Primary completion: 05/03/2019","primary_completion_date":" 05/03/2019","study_txt":" Completion: 05/03/2019","study_completion_date":" 05/03/2019","last_update_posted":"2019-10-01"}]